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Abstract In murine osteoblastic MC3T3-E1 cells which pro-
duced prostaglandin E2 as a bone resorption factor, the
cyclooxygenase-2 induction by tumor necrosis factor K (TNFK)
was suppressed by dexamethasone with an IC50 of 1 nM.
Humulon isolated from hop extract for beer brewing was
reported previously as an inhibitor of bone resorption [Tobe,
H. et al. (1997) Biosci. Biotech. Biochem. 61, 158^159]. We
showed that the compound suppressed the TNFK-dependent
cyclooxygenase-2 induction with an IC50 of as low as about 30
nM as demonstrated experimentally by catalytic activity assay,
Northern blot analysis and promoter analysis. Reporter gene
experiments suggested that humulon blocked the cyclooxygen-
ase-2 expression mediated by NFUB and NF-IL6, but the
intracellular glucocorticoid receptor was not involved. The
catalytic activity of cyclooxygenase-2 was inhibited by humulon
with an IC50 of as high as 1.6 WM. These results showed that
humulon suppressed cyclooxygenase-2 induction at the step of
transcription.
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1. Introduction
It is now well established that there are two isozymes of
prostaglandin (PG)-forming cyclooxygenase; constitutive cy-
clooxygenase-1 and inducible cyclooxygenase-2 [1,2]. MC3T3-
E1 cell cloned from newborn mouse calvaria is an osteogenic
cell line which di¡erentiates into an osteoblast [3,4]. Much
earlier our extensive studies demonstrated the production of
E2 as a major arachidonate metabolite in this cell line [5] and
the induction of cyclooxygenase by various bioregulators [5^
9]. Later the induced enzyme in MC3T3-E1 cells was identi-
¢ed as cyclooxygenase-2 [8^10]. Previously humulon ((R)-
3,5,6-trihydroxy-4,6-bis(3-methyl-2-butenyl)-2-(3-methyl-1-ox-
obutyl)-2,4-cyclohexadien-1-one) (Fig. 1) isolated from hop
(Humulus lupulus L.) extract was found as an inhibitor of
bone resorption (IC50 : 5.9 nM) [11]. We noted this activity
of humulon, and were interested in a possible inhibitory or
suppressive e¡ect of humulon on cyclooxygenase-2 leading to
a decreased production of PGE2 as a bone resorption factor
[12].
2. Materials and methods
2.1. Materials
Humulon was puri¢ed from hop paste as described previously [11],
and the puri¢ed material was dissolved in dimethyl sulfoxide at a
concentration of 10 mM. MC3T3-E1 cells were cultured as described
previously [5]. Con£uent cultures were usually obtained on the 4th
day. Then, the medium was changed to K-MEM (Life Technologies,
Gaithersburg, MD, USA) supplemented with 2% newborn bovine
serum (Irvine Scienti¢c, Santa Ana, CA, USA) and a compound to
be tested. At indicated time intervals, the cells were scraped from
dishes and subjected to various assays described below.
2.2. Assays of cyclooxygenase-1 and -2 activities
For cyclooxygenase-1 preparation, lyophilized powder of sheep
seminal vesicle microsomes (Eldan Technologies, Jerusalem, Israel)
was suspended in 20 mM phosphate bu¡er (pH 7.4) containing
5 mM tryptophan. For cyclooxygenase-2 preparation, 5U107
MC3T3-E1 cells were incubated with 100 nM phorbol 12-myristate
13-acetate and 100 nM A23187 for 9 h. The cells were subjected to
sonic disruption, and centrifuged at 180 000Ug for 50 min. The re-
sultant pellet was collected as the microsomal fraction, and suspended
in 1 ml of 20 mM Tris^HCl (pH 7.4) containing 5 mM tryptophan.
The enzyme assay was performed as described previously [9].
2.3. Cyclooxygenase-2 induction
MC3T3-E1 cells (2.2U106 cells) were incubated with tumor necrosis
factor K (TNFK) (10^20 ng/ml). For determination of PGE2 synthesis,
aliquots were removed from the culture medium (1 ml) of 3U105
MC3T3-E1 cells, and subjected to radioimmunoassay for PGE2 as
described previously [5]. For catalytic activity assay, the cells were
scraped from the dishes, suspended in 200 Wl of 20 mM Tris^HCl
(pH 7.4) containing 5 mM tryptophan, and subjected to sonication.
Aliquots (1^30 Wl) of the sonicate were incubated with 10 WM
[1-14C]arachidonic acid (2.1 GBq/mmol, Amersham Pharmacia Bio-
tech, Bucks, UK) for 2 min at 24‡C in a 100-Wl mixture containing
100 mM Tris^HCl (pH 8.0), 2 WM hematin, and 5 mM tryptophan.
The reaction products were separated by thin-layer chromatography
as described previously [9]. Total RNA was extracted from MC3T3-
E1 cells using ISOGEN (Nippon Gene, Tokyo, Japan) and subjected
to Northern blot analysis for cyclooxygenase-2 and L-actin mRNA as
described previously [8].
2.4. Reporter gene assay
A DNA fragment (nucleotides 3815 to +123) was prepared from
the 5P-£anking region of the mouse cyclooxygenase-2 gene as de-
scribed previously [9], and was inserted into the luciferase plasmid
pGL3 Basic (Promega, Madison, WI, USA). The complementary oli-
gonucleotide with a speci¢c sequence of glucocorticoid response ele-
ment (5P-AGAGGATCTGTACAGGATGTTCTAGAT-3P ; consen-
sus sequence of the glucocorticoid response element is underlined)
was synthesized essentially by the same method as described previ-
ously [9]. The oligonucleotide of the glucocorticoid response element,
NFUB response element [9] or NF-IL6 response element [9] was in-
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serted in front of the herpes simplex virus thymidine kinase gene [13]
of the tk-pGL3 vector [14]. For the transfection of luciferase plasmid,
7.8U105 con£uent cells were treated with pGL3 plasmid DNA (3 Wg),
standard L-galactosidase DNA (1.5 Wg), and 13.5 Wl of Trans IT1-
LT1 (Takara, Tokyo, Japan) in 2.3 ml of serum-free K-MEM for 4 h
at 37‡C. After transfection the medium was changed to 5 ml of K-
MEM with 10% fetal bovine serum (Life Technologies, Gaithersburg,
MD, USA), and the transfected cells were further incubated for 3 days.
The medium was changed to K-MEM described above. After 12 h the
cells were scraped from the dishes, and the luciferase assay was per-
formed as described previously [9]. The results were normalized with
L-galactosidase activity.
3. Results
We investigated the possibility that humulon suppressed the
TNFK-mediated induction of cyclooxygenase-2. When
MC3T3-E1 cells were incubated with 10 ng/ml TNFK in the
presence of humulon for 12 h, the amount of released PGE2
decreased depending on the concentration of humulon with an
IC50 of about 30 nM (Fig. 2A). As shown in Fig. 2C, the
cyclooxygenase activity of the TNFK-treated cells was reduced
by humulon dose-dependently. Furthermore, Northern blot
analysis showed that the addition of humulon suppressed
the TNFK-induced increase of cyclooxygenase-2 mRNA
(Fig. 2E). For analysis of the promoter activity, a luciferase
vector of cyclooxygenase-2 gene was constructed, and trans-
fected to MC3T3-E1 cells by the lipofection method. The
luciferase activity of the cell lysate was measured 12 h after
the addition of 10 ng/ml TNFK in the presence of various
concentrations of humulon (Fig. 2G). Since the same range
of humulon concentration was required for the decrease in the
PGE2 release, enzyme activity, mRNA level and promoter
activity, we presumed that the induction of cyclooxygenase-2
by TNFK was inhibited at the step of transcription. Then, we
examined whether or not humulon inhibited the catalytic ac-
tivities of cyclooxygenases-1 and -2. As shown in Fig. 3, the
cyclooxygenase-1 activity was hardly a¡ected by humulon be-
low 10 WM, whereas the cyclooxygenase-2 activity was inhib-
ited with an IC50 value of about 1.6 WM. Thus, the catalytic
activity of cyclooxygenase-2 was inhibited by humulon, but its
IC50 was higher by about two orders of magnitude than the
IC50 of the cyclooxygenase-2 suppression.
As reported preliminarily earlier [15], the TNFK-dependent
cyclooxygenase-2 induction in MC3T3-E1 cells was sup-
pressed by dexamethasone which is well known as a potent
anti-in£ammatory drug and a suppressor of cyclooxygenase-2
induction in most cells [1,2]. We investigated the e¡ect of
dexamethasone in MC3T3-E1 cells. When the cells were in-
cubated with 20 ng/ml TNFK for 12 h, the amount of released
PGE2 (Fig. 2B) and the cyclooxygenase-2 activity (Fig. 2D)
decreased depending on the concentration of added dexame-
thasone (IC50 : 1 nM). As shown in Fig. 2F, the cyclooxyge-
nase-2 mRNA level was also decreased in the presence of
dexamethasone. The TNFK-dependent luciferase activity was
also decreased by dexamethasone with an IC50 of about 1 nM
(Fig. 2H). These data indicated that dexamethasone sup-
pressed the cyclooxygenase-2 induction by reducing its
mRNA level in MC3T3-E1 cells.
Our previous work with MC3T3-E1 cells demonstrated the
involvement of NFUB and NF-IL6 as transcription factors in
the cyclooxygenase-2 induction by TNFK [9]. We investigated
whether or not humulon and dexamethasone functioned with
the aid of NFUB (nucleotides 3401 to 3393) and NF-IL6
(nucleotides 3138 to 3130) response elements. As shown in
Fig. 4, we constructed a luciferase vector containing thymi-Fig. 1. Structure of humulon.
Fig. 2. E¡ects of humulon and dexamethasone on TNFK-mediated
cyclooxygenase-2 induction. TNFK was present at a concentration
of 10 ng/ml for humulon and 20 ng/ml for dexamethasone. Humu-
lon (A, C, E and G) or dexamethasone (B, D, F and H) was added
at various concentrations. For the PGE2 release assay, 3U105
MC3T3-E1 cells were incubated with TNFK for 12 h (A and B).
For the cyclooxygenase-2 activity assay, 2.2U106 cells were incu-
bated with TNFK for 12 h (C and D). For the cyclooxygenase-2
mRNA assay, 2.2U106 cells were incubated with TNFK for 2 h (E
and F). Total RNA (10 Wg) was applied to Northern blot analysis
for cyclooxygenase-2 mRNA and L-actin mRNA. For the luciferase
assay (G and H), 7.8U105 con£uent cells were transfected with luci-
ferase plasmid including promoter regions of mouse cyclooxygenase-
2 gene. The cells were incubated with TNFK for 12 h. A, B, G and
H are means þ S.D. of triplicate determinations. C, D, E and F are
typical results of the experiments each repeated three times giving
similar results.
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dine kinase gene and NFUB or NF-IL6 response element.
Each vector was transfected to MC3T3-E1 cells, and the lu-
ciferase activity was measured. Both humulon and dexame-
thasone decreased the luciferase activity induced by TNFK.
Thus, the suppressive e¡ect of humulon and dexamethasone
on the cyclooxygenase-2 induction was attributable presum-
ably to NFUB or NF-IL6 or both.
To investigate whether or not humulon bound to glucocor-
ticoid receptor, we used RU486 as a glucocorticoid receptor
antagonist [16]. The TNFK-dependent PGE2 production de-
creased by dexamethasone was reversed by RU486 dose-de-
pendently (Fig. 5A). However, the decreased PGE2 produc-
tion by humulon was not a¡ected by RU486 (Fig. 5A). Then,
we constructed a luciferase vector containing thymidine kinase
gene and glucocorticoid response element (Fig. 5B). The vec-
tor was transfected to MC3T3-E1 cells, and the luciferase
activity of the cell lysate was measured 12 h after the addition
of TNFK plus dexamethasone or humulon. As shown in Fig.
5B, the addition of dexamethasone increased luciferase activ-
ity of MC3T3-E1 cells by 16^18 fold. Therefore, dexametha-
sone bound to the glucocorticoid receptor and then to the
glucocorticoid response element. In contrast, when the trans-
fected cells were incubated with humulon, the luciferase activ- ity was not increased. These data suggested that the humulon-
dependent suppression of cyclooxygenase-2 induction was not
mediated by glucocorticoid receptor.
4. Discussion
As for the inhibitors of cyclooxygenase induction other
than glucocorticoid, a recent paper reported a cyclooxyge-
nase-2 transcription in phorbol ester-treated human epithelial
cells inhibited by resveratrol, which is a phytoalexin found in
grapes and other foods [17]. The compound reduced both the
enzyme activity and the gene transcription at a concentration
in the order of 10 WM. Resveratrol also blocked cyclooxyge-
nase-2 activation by protein kinase C-K, ERK1, and c-Jun
[17]. In addition, sodium salicylate and aspirin at pharmaco-
logical concentrations (0.1^100 WM) inhibited cyclooxygenase-
2 transcription induced by phorbol ester, interleukin-1L, and
lipopolysaccharide (LPS) [18].
It is established that glucocorticoid binds to its intracellular
receptor migrating into nucleus and the steroid-receptor com-
plex binds to a glucocorticoid response element of the pro-
moter region of target gene [19]. Inoue and others reported
Fig. 3. E¡ects of humulon on cyclooxygenase-1 and -2 activities.
The standard cyclooxygenase assays were performed with [1-14C]-
arachidonic acid (10 WM) incubated with the cyclooxygenase-1 of
sheep seminal vesicle microsome (4.3 Wg protein) (closed circle) or
the cyclooxygenase-2 of MC3T3-E1 cell lysate (50 Wg protein) stimu-
lated by phorbol 12-myristate 13-acetate and A23187 (open circle).
Humulon was added at various concentrations. Data are
means þ S.D. of duplicate determinations.
Fig. 4. E¡ect of humulon and dexamethasone on NFUB and NF-
IL6 response elements as examined by the luciferase analysis. Con-
£uent MC3T3-E1 cells (7.8U105) were transfected with luciferase
plasmid including NFUB or NF-IL6 response element. The cells
were incubated for 12 h in the presence or absence of 10 ng/ml
TNFK, 5 WM dexamethasone (DEX) or 10 WM humulon as indi-
cated. Data are means þ S.D. of triplicate determinations.
Fig. 5. Possible binding of humulon and dexamethasone to gluco-
corticoid receptor. A: MC3T3-E1 cells (3U105) were incubated with
10 ng/ml TNFK for 12 h in the absence or presence of 5 WM dexa-
methasone (DEX) or 10 WM humulon. Various concentrations of
RU486 were added. Produced PGE2 was measured using radioim-
munoassay. Data are means þ S.D. of triplicate determinations. B:
Con£uent cells (7.8U105) were transfected with luciferase plasmid
including two glucocorticoid response elements (GRE) and thymi-
dine kinase gene (tk). The cells were incubated for 12 h in the pres-
ence or absence of 10 ng/ml TNFK, 5 WM dexamethasone (DEX) or
10 WM humulon. Data are means þ S.D. of triplicate determinations.
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that the activation of the cyclooxygenase-2 gene promoter by
LPS was suppressed by glucocorticoid, and the suppression
was enhanced by transfection of the glucocorticoid receptor
cDNA to vascular endothelial cells [20]. However, there is no
typical sequence for glucocorticoid response element within
1.2 kb upstream in cyclooxygenase-2 gene promoter [1,2].
One of the two NFUB sites (nucleotides ^223 to ^214) was
involved in both the LPS-induced human cyclooxygenase-2
gene expression in U937 cells and its suppression by dexame-
thasone and herbimycin A [21].
In conclusion, our results demonstrated that humulon has a
glucocorticoid-like suppression activity in TNFK-induced cy-
clooxygenase-2 transcription and its signal transduction may
be independent from glucocorticoid receptor. However, these
results required further investigations of a detailed molecular
mechanism and of in vivo anti-in£ammatory action of humu-
lon.
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